XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Revenues $ 29,000
Operating expenses:    
Research and development 822,000 2,802,000
General and administrative 4,214,000 1,582,000
Total operating expenses 5,036,000 4,384,000
Operating loss (5,036,000) (4,355,000)
Other income (expense):    
Foreign exchange gains (losses) (8,000) 1,000
Interest income 6,000 2,000
Gain on deconsolidation of subsidiary 4,947,000
Other income, net 10,000 52,000
Total other income (expense), net 4,955,000 55,000
Loss before taxes (81,000) (4,300,000)
Income tax benefit 1,354,000
Net loss (81,000) (2,946,000)
Dividend on convertible exchangeable preferred shares
Net loss applicable to common shareholders $ (81,000) $ (2,946,000)
Basic and diluted earnings per common share:    
Net loss per share, basic $ (0.00) $ (2.27)
Net loss per share, diluted $ (0.00) $ (2.27)
Clinical Trial Supply [Member]    
Revenues:    
Revenues $ 29,000